We need your help! Has CancerModels.Org saved you time or effort?

Please take 15 minutes to fill in a survey and help EMBL-EBI make the case for why open data resources are critical to life science research.

Survey link: https://www.surveymonkey.com/r/QGFMBH8

Date of submission: 27/05/2022

Lung Adenocarcinoma

LCF15

Model characterisation

Provided by

Institut Curie - LIP - LC

View data at Curie-LC Contact Curie-LC

License: EMBL-EBI

Patient / Tumour Metadata

Patient Sex
female
Patient Age
40 - 49
Patient Ethnicity
Not Provided
Tumour Type
Primary
Cancer Grade
Not provided
Cancer Stage
T3,N2
Primary Site
lung
Collection Site
lung

PDX model engraftment

PDX model engraftment
HOST STRAIN NAME	SITE	TYPE	MATERIAL	MATERIAL STATUS	PASSAGE
swiss nude	Interscapular Fat Pad	Heterotopic	Tissue Fragment	Fresh	1,3,16

Model quality control

Model quality control
TECHNIQUE	DESCRIPTION	PASSAGE
Histology	high concordance between xenograft and patient tumour	3
Fingerprinting	High concordance between xenograft and patient tumour	1, 16

Model treatment

Model treatment
DRUG	DOSE	PASSAGE	RESPONSE
Cisplatin ChEMBL PubChem	6.0 mg/kg	29	Stable Disease
Docetaxel ChEMBL PubChem	20.0 mg/kg	8	Partial Response
Cisplatin ChEMBL PubChem Paclitaxel ChEMBL PubChem	4.0 mg/kg, 20.0 mg/kg 4.0 mg/kg, 20.0 mg/kg	29 29	Stable Disease Stable Disease
Cisplatin ChEMBL PubChem	6.0 mg/kg	8	Stable Disease
Docetaxel ChEMBL PubChem	20.0 mg/kg	5	Partial Response